证券代码：002612 证券简称：朗姿股份 公告编号：2024-079 朗姿股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 朗姿股份有限公司（以下简称"公司"或"朗姿股份"）第五届董事会第二十五 次会议通知于 2024 年 11 月 8 日以电话、电子邮件等方式发出，于 2024 年 11 月 11 日以通讯及现场会议方式召开。会议由董事长申东日先生主持，会议应出席 董事 5 人，实际出席 5 人。本次会议的召开符合《中华人民共和国公司法》《朗 姿股份有限公司章程》《朗姿股份有限公司董事会议事规则》的有关规定，合法 有效。 二、董事会会议审议情况 1、审议并通过了《关于聘任财务总监的议案》 鉴于公司财务总监常静女士因工作调整原因辞去公司财务总监职务，根据公 司总经理申今花女士的提名，并经提名委员会和审计委员会全体成员同意，聘任 侯立成先生为公司财务总监，任期自本次董事会审议通过之日至第五届董事会任 期届满。具体内容详见公司同日刊登在巨潮资讯网（www.cninfo.com.cn）上的公 告（公告编号：2024-080）。 ...

证券代码：002612 证券简称：朗姿股份 公告编号：2024-082 关于为发行第二期中期票据提供反担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、朗姿股份有限公司（以下简称"公司"或"朗姿股份"）于 2024 年 11 月 11 日召开第五届董事会第二十五次会议，审议通过了《关于为公司发行第二期 中期票据提供反担保的议案》。本期拟发行中期票据金额不超过人民币 1.4 亿元 （含 1.4 亿元）（以下简称"本期票据"或"第二期票据"），为增强本期票据 的偿债保障，由中债信用增进投资股份有限公司（以下简称"中债公司"）为本 期票据发行提供信用增进服务，即中债公司就本期票据存续期发行人应偿还的不 超过人民币 1.4 亿元本金及相应票面利息，提供连带责任保证。同意公司以部分 自有房地产进行抵押，用于向中债公司提供反担保，并授权公司董事长或授权代 理人签署与上述担保及反担保相关的所有法律文件。 2、本次担保不构成关联交易，无需提交股东大会审议。 一、担保情况概述 公司第四届董事会第三十一次会议和 2022 年第二次临时股东大会分别审议 通 ...

证券代码：002612 证券简称：朗姿股份 公告编号：2024-081 朗姿股份有限公司 关于补充确认关联交易暨 2024 年度日常关联交易预计调整 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1．朗姿股份有限公司（以下简称"朗姿股份"或"公司"）于 2024 年 3 月完成 对郑州集美医疗美容医院有限公司（以下简称"郑州集美"）的全部股权收购并将 其纳入公司合并报表范围，2024 年 9 月完成对北京米兰柏羽丽都医疗美容医院 有限公司（以下简称"北京丽都"）全部股权和湖南雅美医疗美容医院有限公司（以 下简称"湖南雅美"）的控制权收购并将其纳入公司合并报表范围。根据相关规则 规定，郑州集美、北京丽都和湖南雅美在其各自纳入公司合并报表前十二个月内 与公司控股股东及其控制主体之间发生的交易构成关联交易。 2. 补充确认相关关联交易暨与同一关联人累计发生关联交易遵循公允合理 的原则，不存在损害公司及全体股东尤其是中小股东利益的行为，不会对关联人 形成较大的依赖，不影响公司的独立性。 一、日常关联交易预计调整基本情况 2024年4月22日，公司 ...

特此公告。 朗姿股份有限公司 关于变更财务总监的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、财务总监辞职的情况 朗姿股份有限公司（以下简称"公司"）董事会于近日收到常静女士的书面 辞呈。常静女士因工作调整原因，辞去公司财务总监的职务。常静女士辞任公司 财务总监后仍继续担任公司副总经理职务，公司日常运营及相关工作不受影响。 常静女士担任公司财务总监期间恪尽职守、勤勉尽责，公司董事会谨此就常静女 士在担任财务总监期间为公司发展所做出的重要贡献表示衷心的感谢。 二、聘任财务总监相关情况 公司于 2024 年 11 月 11 日召开第五届董事会第二十五次会议，审议通过了 《关于聘任财务总监的议案》。根据公司总经理申今花女士的提名，并经提名委 员会和审计委员会全体成员同意，公司董事会同意聘任侯立成先生为公司财务总 监，任期自本次董事会审议通过之日起至第五届董事会届满为止。侯立成先生的 简历详见附件。 证券代码：002612 证券简称：朗姿股份 公告编号：2024-080 朗姿股份有限公司董事会 2024 年 11 月 12 日 附件：侯立成简历 侯立成先生 ...

Investment Rating - The report maintains a "Buy" rating for the company, with a target price reflecting a potential upside of 15% or more compared to the benchmark index [4][9]. Core Views - The company is focusing on synergistic development through both organic growth and external expansion, particularly in the medical aesthetics sector [2][4]. - The third quarter of 2024 showed slight pressure on revenue, but adjusted net profit after excluding non-recurring items demonstrated double-digit growth [2][3]. - The company has made strategic acquisitions to enhance its presence in the upstream medical aesthetics market, which is expected to improve product quality and profitability [3][4]. Financial Performance Summary - For the first three quarters of 2024, the company achieved operating revenue of 4.178 billion yuan, a year-on-year increase of 1.45%. The net profit attributable to the parent company was 209 million yuan, a decrease of 4.87% year-on-year, while the adjusted net profit was 180 million yuan, reflecting an increase of 11.29% year-on-year [2][3]. - The gross margin for the first three quarters of 2024 was 58.92%, an increase of 1.34 percentage points year-on-year, while the net margin was 5.56%, a decrease of 0.17 percentage points year-on-year [3]. - The company has projected earnings per share (EPS) of 0.68, 0.82, and 0.95 yuan for 2024, 2025, and 2026 respectively, with corresponding price-to-earnings ratios (PE) of 24, 20, and 17 times [4][5]. Strategic Acquisitions - In Q3 2024, the company consolidated its financials with the acquisitions of Beijing Lido and Hunan Yamei, which are expected to enhance its medical aesthetics capabilities [3]. - The acquisitions included a 100% stake in Beijing Lido for 330 million yuan and a 70% stake in Hunan Yamei for 252 million yuan, with performance commitments for the next three years [3]. Market Positioning - The company is expanding its business model to encompass three major sectors: medical aesthetics, women's apparel, and children's products, aiming to create a comprehensive beauty industry ecosystem [4].

证券代码：002612 证券简称：朗姿股份 公告编号：2024-078 朗姿股份有限公司 关于重签授信和接受关联方担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、关于重签授信和接受关联方担保的情况 朗姿股份有限公司（以下简称"公司"或"朗姿股份"）于 2024 年 3 月 19 日披 露公司向兴业银行股份有限公司北京金融街支行（以下简称"兴业银行"）申请最 高授信额度 10,000 万元，公司控股股东、实际控制人申东日先生及其配偶翁洁 女士为公司提供保证担保的相关事项，具体详见巨潮资讯网（www.cninfo.com.cn） （公告编号：2024-048）。 为进一步满足日常经营和业务发展资金需要，经公司与兴业银行协商，近日 重新签订授信额度合同，将授信到期日由 2025 年 1 月 25 日延期至 2025 年 10 月 16 日。担保合同随之重新签订，担保期限仍为主合同下债务履行期届满之日起 三年。 公司控股股东、实际控制人申东日先生及其配偶翁洁女士为公司提供本次保 证担保，该担保不向公司收取任何担保费用，也不需要公司提供反担保。 上述授信 ...

Investment Rating - The report maintains a rating of "Accumulate" for the company [2][5]. Core Views - The company's Q3 performance showed weakness, with revenue and net profit declining due to a challenging retail environment [2]. - The company is expanding its medical beauty business through acquisitions and investments, aiming to enhance its upstream supply chain and product offerings [2]. - The earnings forecast for 2024-2025 has been revised downwards, with net profit estimates reduced by 19% and 26% respectively [2]. Financial Performance Summary - For the first three quarters of 2024, the company achieved revenue of 4.18 billion yuan, a year-on-year increase of 13.1%, while net profit was 210 million yuan, a decrease of 4.9% on a comparable basis [2]. - The gross profit margin for the first three quarters improved by 1.6 percentage points to 58.9%, while the net profit margin decreased by 0.3 percentage points to 5.0% [2]. - In Q3 alone, revenue was 1.26 billion yuan, down 6.8% year-on-year, and net profit was 42.25 million yuan, down 17.2% [2]. Business Segment Analysis - The company operates in three main business segments: fashion women's wear, medical beauty, and green baby products, with respective revenue contributions of 38%, 44%, and 17% in the first half of 2024 [2]. - The medical beauty segment is a focus area, with recent acquisitions aimed at expanding downstream operations and enhancing product development capabilities [2]. Earnings Forecast and Valuation - The revised earnings per share (EPS) estimates for 2024, 2025, and 2026 are 0.56 yuan, 0.63 yuan, and 0.71 yuan respectively, with corresponding price-to-earnings (P/E) ratios of 28, 25, and 23 [2][3]. - The report provides a summary of key financial indicators, including projected revenue growth rates and net profit margins for the upcoming years [3].

Investment Rating - The report maintains an "Accumulate" rating for the company [1] Core Views - The company reported a revenue of 4.18 billion yuan for the first three quarters of 2024, representing a year-on-year increase of 1.5%. The net profit attributable to the parent company was 210 million yuan, down 4.9% year-on-year [2] - The company has entered the upstream medical beauty equipment production sector with an investment of 10 million yuan, which is expected to enhance supply chain stability and overall profitability [2] - The gross margin improved year-on-year, with a gross margin of 58.9% for the first three quarters of 2024, up 1.3 percentage points year-on-year [2] - The company aims to build a pan-fashion ecosystem combining medical beauty and clothing, with projected net profits for 2024-2026 of 300 million, 344 million, and 391 million yuan, respectively, reflecting year-on-year growth rates of 33%, 15%, and 14% [2] Financial Performance Summary - Total revenue (in million yuan) is projected to grow from 5,145 in 2023 to 7,160 in 2026, with year-on-year growth rates of 32.64%, 10.00%, 12.41%, and 12.56% for the respective years [1][8] - The net profit attributable to the parent company is expected to increase from 225 million yuan in 2023 to 391 million yuan in 2026, with year-on-year growth rates of 953.37%, 33.34%, 14.63%, and 13.74% [1][8] - The latest diluted EPS is projected to rise from 0.51 yuan in 2023 to 0.88 yuan in 2026, with corresponding P/E ratios of 31.14, 23.35, 20.37, and 17.91 for the same years [1][8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a slight operational pressure in Q3, with its medical beauty business expanding further. The revenue for Q1-Q3 2024 reached 4.178 billion yuan, a year-on-year increase of 1.45%, while the net profit attributable to shareholders was 209 million yuan, a decrease of 4.87% [3][4] - The company has integrated 40 medical beauty institutions into its operations, with a steady increase in gross margin to 58.9% for Q1-Q3 2024, reflecting a 1.6 percentage point increase [4] - The company is pursuing a comprehensive strategy to enhance its presence in the beauty industry through external expansion, vertical integration, and horizontal diversification [5] Summary by Sections Financial Performance - For Q3 2024, the company achieved revenue of 1.265 billion yuan, a decrease of 6.80%, and a net profit of 42 million yuan, down 17.21% [3] - The projected net profits for 2024-2026 are 316 million yuan, 389 million yuan, and 465 million yuan, respectively, with corresponding EPS of 0.71, 0.88, and 1.05 yuan [3][6] Business Expansion - The company has expanded its medical beauty business by acquiring institutions such as Beijing Lido and Hunan Yamei, and aims to enhance its supply chain stability and procurement capabilities through investments in upstream products [4][5] - The launch of the community-oriented beauty brand "Jingfu Meise" indicates the company's strategy to explore the dual beauty model of "medical beauty + lifestyle beauty" [5] Financial Metrics - The company’s gross margin for Q1-Q3 2024 was 58.9%, with stable operating expense ratios across sales, management, R&D, and financial costs [4] - The projected revenue growth rates for 2024-2026 are 16.6%, 11.7%, and 10.3%, respectively, indicating a robust growth trajectory [6]

Investment Rating - The report maintains an "Outperform" rating for the company [4][5]. Core Views - The company reported Q3 results that fell short of market expectations, with Q3 net profit under pressure. For the first three quarters of 2024, revenue was 4.178 billion yuan, a year-on-year increase of 1.45%, while net profit attributable to shareholders was 209 million yuan, a year-on-year decrease of 4.87% [4][5]. - The company is a regional leader in the medical beauty sector and has strong incubation capabilities. It has announced the establishment of a new entity to enter upstream medical device production, enhancing supply chain stability and bargaining power [4][5]. - The company operates in three main segments: fashion women's wear, green baby products, and medical beauty, and plans to continue expanding through both organic growth and acquisitions [5]. Financial Summary - For the first three quarters of 2024, the gross margin was 58.92%, an increase of 1.34 percentage points, while the net profit margin was 5.01%, a decrease of 0.24 percentage points [4][5]. - The company expects net profits for 2024 to be 304 million yuan, with projected growth rates of 35.1% in 2024, 14.2% in 2025, and 17.1% in 2026 [6][5]. - The company’s revenue for 2024 is projected to be 5.918 billion yuan, with a year-on-year growth rate of 15% [6][5].